Trial Profile

Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Axitinib; Everolimus; Lenvatinib; Pazopanib; Sorafenib; Sunitinib
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms US NIS Cabo
Sponsors Ipsen

11 Nov 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
13 Feb 2021 Status changed to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com